NR4A1 and breast cancer: The aim of this study is to evaluate the potential value of biological markers (Her2/neu, p53, and hormonal receptor status) for the prediction of disease outcome and response to therapy in patients with locally advanced breast cancer, after neoadjuvant chemotherapy.